Parkinson’s Clinical Trials: MDS Highlights
- Here's a breakdown of the data from the provided text, organized for clarity:
- * Risvodetinib: A potential treatment for Parkinson's Disease (PD) studied in a Phase 2 trial.
- Conference Presentation Details (All presented at the 2025 MDS Congress, October 5-9, 2025, Honolulu, HI):
Here’s a breakdown of the data from the provided text, organized for clarity:
Key Topics Discussed:
* Risvodetinib: A potential treatment for Parkinson’s Disease (PD) studied in a Phase 2 trial.
* VTX3232 (Ventyx Biosciences): A CNS-penetrant NLRP3 inhibitor with a good safety profile shown in a Phase 2a trial.
* hESC-derived dopaminergic progenitors: Human embryonic stem cell-derived cells implanted in patients with PD, results from a Phase 1/2a trial.
Conference Presentation Details (All presented at the 2025 MDS Congress, October 5-9, 2025, Honolulu, HI):
* Risvodetinib: Presented by M. Werner, C. Meyer, E.Mancino,C. Klint, J. Pellectchia, A. McGarry, Keburtz, C. Olrow.
* VTX3232: Presented by Gregg R.,Christianson C., Liu K., et al. (Abstract LBA-12).
* hESC-derived dopaminergic progenitors: Presented by Na H. et al. (Abstract LBA-13).
Source:
* Healio Interviews
Disclosures (Dr. Deik):
* Consultant: Amneal Pharmaceuticals, Genus Lifesciences, Manifold Bio, SPARK-NS
* Scientific Advisory/Data Safety Monitoring Boards: Amneal Pharmaceuticals, Supernus Therapeutics
* Royalties: uptodate and Elsevier (health care publications)
* Research Support: amylyx Therapeutics, Annovis Bio, AskBio, Cerevel Therapeutics, Lundbeck Therapeutics, Ono Pharmaceuticals, Prevail Therapeutics, Teva pharmaceuticals, and the Dystonia Coalition/Dystonia Medical Research Foundation.
Healio AI Promotion:
* The article includes a promotion for Healio AI, a tool for accessing clinical information from sources like PubMed, trials, guidelines, and Healio’s news coverage.